Purification and Characterization of a Novel Hyaluronan-Binding Protein (PHBP) from Human Plasma: It Has Three EGF, a Kringle and a Serine Protease Domain, Similar to Hepatocyte Growth Factor Activator
Abstract:A novel hyaluronan-binding protein (PHBP) was purified from human plasma by affinity chromatography on hyaluronan-conjugated Sepharose. The contaminating IgM and albumin in the partially purified preparation were removed with anti-IgG antibody-conjugated Sepharose and anti-albumin antibody-conjugated Sepharose, respectively, and no other contaminant was observed. Finally, 800 micrograms of PHBP was isolated from 500 ml of human plasma. PHBP gave a single 70-kDa band on SDS-PAGE under non-reducing conditions, a… Show more
“…A human protein similar to HGFA has recently been identified (22,23) (GenBank TM accession number AAB46909). This molecule, hyaluronin-binding protein, was only 38% identical to murine HGFA at the amino acid level.…”
Section: Resultsmentioning
confidence: 99%
“…However, other members of the plasminogen activator family, coagulation factor XII, tissue plasminogen activator (tPA), and urokinase (uPA), are also weak activators of HGF (11,15,16). An HGFAlike molecule, PHBP, has recently been identified and could potentially, based on its sequence, activate HGF (22,23). Two of these enzymes, tPA and uPA, are also expressed in developing kidney (29).…”
The interaction of hepatocyte growth factor (HGF) with c-Met has been implicated in morphogenesis of the kidney, lung, mammary gland, liver, placenta, and limb bud. HGF is secreted as an inactive zymogen and must be cleaved by a serine protease to initiate Met signaling. We show here that a serine protease specific for HGF, HGF activator (HGFA), is expressed and activated by the ureteric bud of the developing kidney in vivo and in vitro. Inhibition of HGFA activity with serine protease inhibitors reduced ureteric bud branching and inhibited glomerulogenesis and nephrogenesis. Activated HGF rescued developing kidneys from the effects of inhibitors. HGFA was localized around the tips of the ureteric bud in developing kidneys, while HGF was expressed diffusely throughout the mesenchyme. These data show that expression of HGF is not sufficient for development, but that its activation is also required. The localization of HGFA to the ureteric bud and the mesenchyme immediately adjacent to it suggests that HGFA creates a gradient of HGF activity in the developing kidney. The creation and shape of gradients of activated HGF by the localized secretion of HGF activators could play an important role in pattern formation by HGF responsive tissues.
“…A human protein similar to HGFA has recently been identified (22,23) (GenBank TM accession number AAB46909). This molecule, hyaluronin-binding protein, was only 38% identical to murine HGFA at the amino acid level.…”
Section: Resultsmentioning
confidence: 99%
“…However, other members of the plasminogen activator family, coagulation factor XII, tissue plasminogen activator (tPA), and urokinase (uPA), are also weak activators of HGF (11,15,16). An HGFAlike molecule, PHBP, has recently been identified and could potentially, based on its sequence, activate HGF (22,23). Two of these enzymes, tPA and uPA, are also expressed in developing kidney (29).…”
The interaction of hepatocyte growth factor (HGF) with c-Met has been implicated in morphogenesis of the kidney, lung, mammary gland, liver, placenta, and limb bud. HGF is secreted as an inactive zymogen and must be cleaved by a serine protease to initiate Met signaling. We show here that a serine protease specific for HGF, HGF activator (HGFA), is expressed and activated by the ureteric bud of the developing kidney in vivo and in vitro. Inhibition of HGFA activity with serine protease inhibitors reduced ureteric bud branching and inhibited glomerulogenesis and nephrogenesis. Activated HGF rescued developing kidneys from the effects of inhibitors. HGFA was localized around the tips of the ureteric bud in developing kidneys, while HGF was expressed diffusely throughout the mesenchyme. These data show that expression of HGF is not sufficient for development, but that its activation is also required. The localization of HGFA to the ureteric bud and the mesenchyme immediately adjacent to it suggests that HGFA creates a gradient of HGF activity in the developing kidney. The creation and shape of gradients of activated HGF by the localized secretion of HGF activators could play an important role in pattern formation by HGF responsive tissues.
“…In the remaining population, follow-up was 96.5% (nϭ826) and 95.6% (nϭ684) complete, respectively. [1][2][3] Blood specimens for DNA extraction were drawn as part of the 1995 follow-up. Adequate polymerase chain reaction products were not obtainable in 16 samples, which left 810 (1995) and 678 (2000) subjects for the main analysis.…”
Section: Study Subjectsmentioning
confidence: 99%
“…The plasmatic serine protease factor seven-activating protease (FSAP) has been recognized as a novel potent activator of prourokinase-dependent fibrinolysis. [1][2][3][4][5][6] We recently characterized a single nucleotide polymorphism (SNP) of FSAP, termed "Marburg I polymorphism," which impairs the capacity of FSAP to activate prourokinase without attenuating its potential contribution to the extrinsic coagulation pathway. 4 -6 This may drive hemostasis toward a prothrombotic state.…”
Background-Atherothrombosis is a main pathomechanism in the evolution of vessel stenosis and is counteracted by endogenous fibrinolysis. Recently, the plasmatic serine protease "factor seven-activating protease" (FSAP) was recognized as a potent activator of prourokinase in vitro. The Marburg I polymorphism of FSAP impairs this potential and may thus facilitate arterial thrombosis. Methods and Results-This analysis of the Bruneck Study involved 810 men and women aged 40 to 79 years. The ultrasound-based atherosclerosis progression model (5-year follow-up) permits differentiation between early atherogenesis and the advanced stenotic stages of carotid artery disease. The FSAP Marburg I polymorphism was found in 37 subjects (carriage rate 4.4%). Individuals with this genetic variant showed a prominently reduced in vitro capacity to activate prourokinase. No relation was found to exist between the Marburg I polymorphism and early atherogenesis. In contrast, it emerged as a strong and independent risk predictor of incident/progressive carotid stenosis (multivariate odds ratio [95%CI], 6.6 [1.6 to 27.7]). This finding equally applied to subjects with and without co-segregation of the Marburg II polymorphism. The risk profile of advanced atherogenesis further includes cigarette smoking, high lipoprotein(a), the factor V Leiden mutation, low antithrombin III, high fibrinogen, and diabetes. Conclusions-In concert with other genetic and acquired conditions known to interfere with coagulation or fibrinolysis, the Marburg I polymorphism of FSAP, which attenuates its capacity to activate prourokinase, is a significant risk predictor for the evolution and progression of carotid stenosis.
“…FSAP was identified by a number of investigators and isolated either because of its affinity for immobilized hyaluronic acid 7 or its presence in commercial prothrombin complex concentrates. 8 The protein contains domain structures frequently associated with coagulation and fibrinolytic enzymes, including three "EGF"-like domains, a "kringle," and a serine protease domain.…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.